Incyte Corp (INCY)

136.28
NASDAQ : Health Care
Prev Close 135.63
Day Low/High 133.83 / 136.86
52 Wk Low/High 71.75 / 153.15
Avg Volume 2.03M
Exchange NASDAQ
Shares Outstanding 204.77M
Market Cap 27.77B
EPS 0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-to-Severe Rheumatoid Arthritis Presented At EULAR 2017

- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo

Domino's Pizza, Xylem, Incyte, Mercadolibre: 'Mad Money' Lightning Round

Domino's Pizza, Xylem, Incyte, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Domino's Pizza, Xylem, and Incyte, but he's waiting for better pricing for NXP Semiconductor.

Navigating Strong Crosscurrents: Cramer's 'Mad Money' Recap (Tuesday 6/13/17)

Navigating Strong Crosscurrents: Cramer's 'Mad Money' Recap (Tuesday 6/13/17)

Jim Cramer says the markets could be further rattled by the Federal Reserve meeting.

Lilly To Present New Data On Olumiant® (baricitinib) In Rheumatoid Arthritis And Taltz® (ixekizumab) In Psoriatic Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017)

Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday,...

Incyte Cancer Drug Data Is 'Compelling,' Credit Suisse Says

Incyte Cancer Drug Data Is 'Compelling,' Credit Suisse Says

Credit Suisse analyst Alethia Young isn't worried about Incyte.

Incyte Analyst And Investor Event To Highlight Clinical Data Presentations From ASCO 2017

Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed...

Clinical Trial Data For Combination Of Epacadostat And Opdivo® (nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...

Updated Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study

Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.

Combination Of Incyte's Epacadostat Plus Merck's KEYTRUDA® (pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17

Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17

Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARR, AYA, CMCT, CRMT, INCY, NMR Downgrades: ASC, CPLP, FITB, MTRX, PAM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017...

Tanger Factory Outlet Centers, Gilead Sciences, Qorvo: 'Mad Money' Lightning Round

Tanger Factory Outlet Centers, Gilead Sciences, Qorvo: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Tanger Factory Outlet Centers, Gilead Sciences, and Qorvo in the 'Mad Money' Lightning Round.

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Jim Cramer is bullish on Walgreens Boots Alliance, Becton Dickinson, and General Mills.

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Money managers are piling back into growth stocks without hesitation, says Jim Cramer.

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

First Data From Combination Of Epacadostat With Opdivo® (nivolumab) Will Be Highlighted At ASCO 2017

Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's...

New Data For Presentation At ASCO 2017 Reinforce Clinical Profile Of Epacadostat In Combination With Keytruda® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with Keytruda ®...

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.